Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Regeneron CEO: Amgen not putting patients first

Regeneron CEO Len Schleifer ripped into Amgen for its insistence on blocking sales of a rival cholesterol drug during the appeals process in a patent infringement case.

Read More »

Benefits of new cancer drugs vary widely

Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits vary depending on the drug, a new study shows.

Read More »

Democrats lean on drug pricing as ACA repeal looms

Democrats are showing little interest in cooperating with the Republicans who control Congress on legislation to dismantle the Obamacare health insurance law, but some are signaling a willingness to collaborate on action to curb rising drug prices.

Read More »

Express Scripts: No let-up in drug pricing chatter

Express Scripts Holding Co. – the largest pharmacy benefit manager in the United States – signaled that scrutiny into drug pricing is not going away.

Read More »

New diabetes guidelines imminent, Jardiance sales may surge

Two leading U.S. medical societies are poised to issue new diabetes treatment guidelines that are expected to reflect the lifesaving cardiovascular effects of Eli Lilly’s Jardiance.

Read More »

Global prescription drug spend seen at $1.5 trillion in 2021: report

Global spending on prescription medicines will reach nearly $1.5 trillion by 2021, although the annual rate of growth will decrease from recent years, according to a forecast by Quintiles IMS Holding.

Read More »

Healthcare Agency Roundtable 2016

Management from 2016 Manny Award winners and finalists weigh in on various industry topics presented to them by Med Ad News.

Read More »

Novo, Sanofi face off with new diabetes drugs

Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.

Read More »

NICE U-Turns, Backs Approval of Roche’s Perjeta

The National Institute for Clinical Excellence has finally given backing for the NHS’ approval of Perjeta for human epidermal growth factor receptor 2-positive breast cancer.

Read More »

No early win for cholesterol drug Praluent

Sanofi and Regeneron will continue a large clinical outcomes study for the injectable cholesterol-lowering drug Praluent, confounding hopes of an early win.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom